Achyut Healthcare Limited has received formal approval from BSE Limited for migrating its equity shares from the BSE SME platform to the BSE Main Board Platform. The pharmaceutical company received this approval through BSE Limited's communication dated January 01, 2026, marking a significant corporate milestone. The approval was granted under reference number LO/Migration/SN/MIG-TP/634/2025-26, completing the regulatory framework requirements for platform migrations.
The company's equity shares will commence trading on the BSE Main Board Platform from Friday, January 02, 2026. Achyut Healthcare Limited will maintain its existing BSE script code 543499 following the migration. This transition represents the culmination of the migration process and provides investors with enhanced market access through the main board platform.
Achyut Healthcare Limited has fulfilled all regulatory requirements for the migration process. The company communicated this development pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring complete compliance with disclosure obligations. The migration approval demonstrates the company's adherence to regulatory standards required for main board listing.
Achyut Healthcare Limited, formerly known as Achyut Healthcare Private Limited, operates in the pharmaceutical sector. The company maintains its registered office in Ahmedabad, Gujarat, with additional corporate and administrative facilities in the region. The migration to the main board platform represents a significant advancement in the company's market presence and provides broader investor accessibility.
